Jump to content

Drilldown: Medicines

Choose a table:


Medicines > classes : 5HT1A activity than aripiprazole or Antidepressant or Tryptamine

Use the filters below to narrow your results.

generic:
brand:
None (27) · Anafranil (1) · Aurorix (1) · Cymbalta, Drizalma Sprinkle, Irenka, Yentreve (1) · Edronax (1) · Fetzima (1) · Ludiomil (1) · Marplan (1) · Nardil (1) · Norpramin (1) · Parnate (1) · Rexulti (1) · Savella (1) · Serzone (1) · Stablon (1) · Surmontil (1) · Tofranil (1) · Valdoxan (1) · Vivactil (1) · Zoloft (1)
classes: (Click arrow to add another value)
mechanism:
5-HT2A agonist (15) · 5-HT2A agonist; 5-HT3 antagonist (1) · 5-HT2A agonist; minor psilocybin mushroom alkaloid (1) · 5-HT2A agonist; primarily auditory effects (1) · 5-HT2A agonist; sigma-1 agonist (1) · Irreversible non-selective MAO inhibitor (3) · Melatonin receptor agonist; 5-HT2C antagonist (1) · Monoamine releasing agent; 5-HT2A agonist; MAO inhibitor (1) · Mu-opioid agonist; modulates glutamate AMPA receptors (1) · Partial agonist at D2 and 5HT1A. Antagonist at 5HT2A, α1A, α1B, α2C. More potent 5HT2A antagonism, 5HT1A partial agonism, and α1 antagonism (relative to D2 partial agonism) than aripiprazole, proposed to reduce akathisia and enhance affective/cognitive effects. (1) · Potent 5-HT2A agonist; sigma-1 agonist (1) · Potent serotonin reuptake inhibitor; also NRI (1) · Prodrug of 4-HO-DET; 5-HT2A agonist (1) · Prodrug of 4-HO-DiPT; 5-HT2A agonist (1) · Prodrug of 4-HO-MET; 5-HT2A agonist (1) · Prodrug of 4-HO-MiPT; 5-HT2A agonist (1) · Prodrug of psilocin; 5-HT2A agonist (1) · Reversible inhibitor of MAO-A (1) · Selective norepinephrine reuptake inhibitor (3) · Serotonin and norepinephrine reuptake inhibitor (3) · Serotonin reuptake inhibitor and 5-HT2A antagonist (1) · Serotonin–norepinephrine reuptake inhibition (balanced) (1) · Serotonin–norepinephrine reuptake inhibitor (2) · TrkB/BDNF'"`UNIQ--ref-00000084-QINU`"' '"`UNIQ--vote-00000085-QINU`"' (1) · Weak SRI; primarily H1/D2/alpha antagonist (1)
uses:
None (44) · Depression, anxiety, neuropathic pain, fibromyalgia, chronic musculoskeletal pain (1) · Schizophrenia (FDA-approved 2015). Adjunctive treatment of major depressive disorder (2015). '''Agitation associated with dementia due to Alzheimer disease''' (FDA-approved May 2023, first agent specifically approved for this problem). Investigational for PTSD (combined with sertraline). (1)
starting dose:
None (44) · 25 mg (1) · Schizophrenia: 1 mg PO daily × 4 days, then 2 mg daily × 3 days, then 4 mg daily. MDD adjunct: 0.5-1 mg daily, increase to 2 mg max. AD agitation: 0.5 mg daily, titrate to 2-3 mg daily. (1)
preparations:
None (44) · 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, 4 mg tablets (1) · 25 mg, 50 mg, 100 mg tablets; oral concentrate 20 mg/mL (1)
fda max:
None (44) · 200 mg/d (1) · 4 mg/d (schizophrenia); 3 mg/d (AD agitation); 3 mg/d (MDD adjunct) (1)
routes:
None (43) · Oral (3)
onset:
None (43) · Anxiolysis classically 3-4 weeks, continuing improvement to 8-12 weeks (1) · Mood: 2–4 weeks. Pain: often within 1–2 weeks. (1) · Weeks for psychosis/depression; AD agitation benefit emerges over weeks (1)
duration:
None (43) · Chronic daily dosing (1) · Daily dosing (1) · Long (1)
halflife:
None (43) · ~12 hours (1) · ~26 h (sertraline; range 13-45 h, longer in females); ~62-104 h (N-desmethylsertraline, weakly active) (1) · ~91 hours (1)
bioavailability:
None (43) · Absolute bioavailability not precisely characterized; food modestly increases exposure (1) · ~50% (highly variable) (1) · ~95% (1)
pregnancy:
None (43) · Category C (1) · Category C'"`UNIQ--ref-0000008F-QINU`"' (1) · Limited data; National Pregnancy Registry available (1)
legal:
None (43) · Rx (1) · Rx-only (1) · Rx-only in US (1)

Showing below up to 46 results in range #1 to #46.

View (previous 250 | next 250) (20 | 50 | 100 | 250 | 500)


View (previous 250 | next 250) (20 | 50 | 100 | 250 | 500)

Retrieved from "https://pharmacopedia.wiki/p/Special:Drilldown/Medicines"